Verve Hits The Clinic With Gene-Edited Cholesterol-Lowering Drug

 
• By Alaric DeArment
Verve announced the dosing of the first patient in the trial of its Phase Ib study of VERVE-101 in HeFH • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies